www.neurologiepropraxi.cz / Neurol. praxi. 2024;25(4):267-273 / NEUROLOGIE PRO PRAXI 273 HLAVNÍ TÉMA Novinky v diagnostické patologii nádorů hypofýzy – klinickopatologická perspektiva 134. doi:10.1530/EJE-18-0749. 7. Colao A, Pivonello R, Scarpa R, et al. The acromegalic arthro‑ pathy. J Endocrinol Invest. 2005;28(8 Suppl.):24-31. 8. Drummond J, Roncaroli F, Grossman AB, et al. Clinical and Pathological Aspects of Silent Pituitary Adenomas. J Clin Endocrinol Metab. 2019;104(7):2473-2489. doi:10.1210/ jc.2018-00688. 9. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pitu‑ itary adenomas: a systematic review. Cancer. 2004;101(3):613619. doi:10.1002/cncr.20412. 10. Fassett DR, Couldwell WT. Metastases to the pituitary gland. Neurosurg Focus. 2004;16(4):E8. 11. Guerrero‑Perez F, Marengo AP, Vidal N, et al. Primary tu‑ mors of the posterior pituitary: a systematic review. Rev Endocr Metab Disord. 2019;20(2):219-238. doi:10.1007/s11154019-09484-1. 12. Chen J, Jian X, Deng S, et al. Identification of recurrent USP48 and BRAF mutations in Cushing’s disease. Nat Commun. 2018;9(1):3171. doi:10.1038/s41467-018-05275-5. 13. Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo ‑pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab. 2020;85(4):1370-1376. doi:10.1210/jcem.85. 4. 6501. 14. Kwancharoen R, Blitz AM, Tavares F, et al. Clinical features of sellar and suprasellar meningiomas. Pituitary. 2014;17(4):342348. doi:10.1007/s11102-013-0507-z. 15. Lavrentaki A, Paluzzi A, Wass JA, et al. Epidemiolo‑ gy of acromegaly: review of population studies. Pituitary. 2017;20(1):4-9. doi:10.1007/s11102-016-0754-x. 16. Lopes MB, Sloan E, Polder J. Mixed Gangliocytoma ‑Pituitary Adenoma: Insights on the Pathogenesis of a Rare Sellar Tumor. Am J Surg Pathol. 2017;41(5):586-595. doi:10.1097/ PAS.0000000000000806. 17. Lu L, Wan X, Xu Y, et al. Prognostic Factors for Recurren‑ ce in Pituitary Adenomas: Recent Progress and Future Di‑ rections. Diagnostics (Basel). 2022;12(4). doi:10.3390/diagnos‑ tics12040977. 18. McDowell BD, Wallace RB, Carnahan RM, et al. Demogra‑ phic differences in incidence for pituitary adenoma. Pituitary. 2011;14(1):23-30. doi:10.1007/s11102-010-0253-4. 19. Mete O, Lopes MB, Asa SL. Spindle cell oncocytomas and granular cell tumors of the pituitary are variants of pituicy‑ toma. Am J Surg Pathol. 2013;37(11):1694-1699. doi:10.1097/ PAS.0b013e31829723e7. 20. Muller HL, Merchant TE, Warmuth‑Metz M, et al. Craniopharyngioma. Nat Rev Dis Primers. 2019;5(1):75. doi:10.1038/ s41572-019-0125-9. 21. Neou M, Villa C, Armignacco R, et al. Pangenomic Classi‑ fication of Pituitary Neuroendocrine Tumors. Cancer Cell. 2020;37(1):123-134 e125. doi:10.1016/j.ccell.2019. 11. 002. 22. Nishioka H, Inoshita N, Mete O, et al. The Complementa‑ ry Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. Endocr Pathol. 2015;26(4):349-355. doi:10.1007/s12022-015-9398-z. 23. Ostrom QT, Francis SS, Barnholtz‑Sloan JS. Epidemiolo‑ gy of Brain and Other CNS Tumors. Curr Neurol Neurosci Rep. 2021;21(12):68. doi:10.1007/s11910-021-01152-9. 24. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tu‑ mors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018;20(suppl_4), iv1-iv86. doi:10.1093/neuonc/noy131. 25. Papanikolaou N, Millar O, Coulden A, et al. Clinical charac‑ teristics of functioning gonadotroph adenoma in women pre‑ senting with ovarian hyperstimulation: Audit of UK pituitary centres. Clin Endocrinol (Oxf). 2023;99(4):386-395. doi:10.1111/ cen.14949. 26. Ragnarsson O, Olsson DS, Chantzichristos D, et al. The in‑ cidence of Cushing’s disease: a nationwide Swedish study. Pituitary. 2019;22(2):179-186. doi:10.1007/s11102-019-00951-1. 27. Shimon I. Metastatic Spread to the Pituitary. Neuroendocrinology. 2020;110(9-10):805-808. doi:10.1159/000506810. 28. Schmid S, Solomon DA, Perez E, et al. Genetic and epigene‑ tic characterization of posterior pituitary tumors. Acta Neuropathol. 2021;142(6):1025-1043. doi:10.1007/s00401-021-02377-1. 29. Teears RJ, Silverman EM. Clinicopathologic re‑ view of 88 cases of carcinoma metastatic to the putui‑ tary gland. Cancer. 1975;36(1):216-220. doi:10.1002/10970142(197507)36:1<216:aid‑cncr2820360123>3. 0. co;2-e. 30. Trouillas J, Roy P, Sturm N, et al. A new prognostic clini‑ copathological classification of pituitary adenomas: a multi‑ centric case‑control study of 410 patients with 8 years post ‑operative follow‑up. Acta Neuropathol. 2013;126(1):123-135. doi:10.1007/s00401-013-1084-y. 31. Villa C, Vasiljevic A, Jaffrain‑Rea ML, et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) proposal. Virchows Arch. 2019a;475(6):687-692. doi:10.1007/ s00428-019-02655-0. 32. Villa C, Vasiljevic A, Jaffrain‑Rea ML, et al. A standardised diagnostic approach to pituitary neuroendocrine tumours (PitNETs): a European Pituitary Pathology Group (EPPG) pro‑ posal. Virchows Arch. 2019 b. doi:10.1007/s00428-019-02655-0 33. WHO. (2021). World Health Organization Classification of Tumours of the Central Nervous System. (5th ed.). Lyon: In‑ ternational Agency for Research on Cancer. ODBORNÝ GARANT: prof. MUDr. Aleš Linhart, DrSc. POŘADATEL: Společnost SOLEN, s. r. o., ve spolupráci s II. interní klinikou kardiologie a angiologie 1. LF UK a VFN v Praze ZLATÝ PARTNER POČET KREDITŮ 2 Registrace ZDARMA TERMÍN duben 2024 až březen 2025 dostupný na online.solen.cz ON LINE KURZ OBSAH KURZU Teoreticky o Fabryho chorobě – MUDr. Kristýna Bayerová, Centrum pro Fabryho chorobu, VFN Praha Jak nepřehlédnout pacienta – s Fabryho chorobou v praxi kardiologa? – MUDr. Mária Vyskočilová, FN Brno Prakticky o Fabryho chorobě – MUDr. Kristýna Bayerová, Centrum pro Fabryho chorobu, VFN Praha Diskuze Fabryho choroba – MUDr. Gabriela Dostálová, II. interní klinika – Kardiologie a angiologie 1. LF UK a VFN v Praze Propojení Fabryho choroby: diagnostika a léčba u pacientů s Fabryho chorobou
RkJQdWJsaXNoZXIy NDA4Mjc=